Gabriel Garcia

Gabriel Garcia

Auto-generated profile, based on publicly available information

Gabriel Garcia

Centro de Investigaciones Respiratorias de La Plata, La Plata, Argentina

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2024 in Pulmonary Therapy
Verified
Journal Article
Open access
PDF file
RCRicardo de Amorim Correa
Ricardo de Amorim Correa
FAFrancisco Eleodoro Arancibia
Francisco Eleodoro Arancibia
RKRenato Kfouri
Renato Kfouri
ACAlberto Chebabo
Alberto Chebabo
GGGabriel García
Gabriel García
OCOtavio Augusto Leite Cintra
Otavio Augusto Leite Cintra
Respiratory syncytial virus (RSV) is a significant global health concern and major cause of hospitalization, particularly among infants and older adults. The clinical impact of RSV is well characterized in infants; however, in many countries, the burden and risk of RSV in older populations are overlooked. In Latin America, there are limited data on RSV epidemiology and disease management in older adults. Therefore, the impact of RSV in this region needs to be addressed. Here, current insights on RSV infections in older populations in Latin America, including those with underlying health conditions, are discussed. We also outline the key challenges limiting our understanding of the burden of RSV in Latin America in a worldwide context and propose an expert consensus to improve our understanding of the burden of RSV in the region. By so doing, we aim to ultimately improve disease management and outcomes of those at risk and to alleviate the impact on healthcare systems. A graphical plain language summary is available with this article. Graphical Plain Language Summary

4 August 2022 in Respiratory Medicine
Verified
Journal Article
Open access
Giorgio Walter CanonicaGiorgio Walter Canonica
Giorgio Walter Canonica
ASAntonio Spanevello
Antonio Spanevello
LLLuis Pérez de Llano
Luis Pérez de Llano
CRChristian Domingo Ribas
Christian Domingo Ribas
JBJohn D. Blakey
John D. Blakey
ABAman Kapil Butta
Aman Kapil Butta
Purpose: Definitions and measures of asthma control used in clinical trials and in clinical practice vary considerably. There is also misalignment between patients and healthcare professionals (HCPs) in terms of understanding and managing asthma control. This study aimed to progress towards a consensus definition of asthma control, and evaluate disparities between HCP and patient perspectives. Basic procedures: A two-stage Delphi questionnaire involving asthma specialists sought to identify areas of consensus on aspects of asthma control in clinical practice. Results were compared with those of a structured literature review to assess if existing guidance and measures of asthma control used in studies correlated with practice. Eighty-two panelists took part in the Delphi questionnaire. The structured literature review included 185 manuscripts and 31 abstracts. Main findings: Panelists agreed that there was no standard definition of asthma control, confirmed by a total of 19 different composite consensus/guideline definitions and/or validated measures of control being identified across the Delphi study and literature review. Panelists agreed on the positive associations of well-controlled asthma with patient outcomes, but not on the components or thresholds of a working definition of control. Principal conclusions: A universally accepted definition and measure of asthma control that is utilized and understood by patients, HCPs, and researchers is required.

24 November 2023 in Respiratory Medicine
Verified
Journal Article
Open access
NRNicolas Roche
Nicolas Roche
AYArzu Yorgancıoğlu
Arzu Yorgancıoğlu
ACAlvaro Augusto Cruz
Alvaro Augusto Cruz
GGGabriel Garcia
Gabriel Garcia
KLKim L. Lavoie
Kim L. Lavoie
SCSwarnendu Chatterjee
Swarnendu Chatterjee
Asthma treatments based solely on diagnostic label do not benefit patients equally. To identify patient traits that may be associated with improved treatment response to regular inhaled corticosteroid (ICSs) dosing with short-acting β2-agonist reliever or ICS/formoterol-containing therapy, a systematic literature review (SLR) was conducted. Searches of databases including MEDLINE and Embase identified randomised controlled trials (RCTs) of patients with asthma, aged ≥12 years, published 1998-2022, containing ≥1 regular ICS dosing or ICS/formoterol-containing treatment arm, and reporting patient traits and outcomes of interest. Relevant data was extracted and underwent a feasibility assessment to determine suitability for meta-analysis. The SLR identified 39 RCTs of 72,740 patients and 90 treatment arms, reporting 11 traits and 11 outcomes. Five patient traits (age, body mass index, FEV1, smoking history, asthma control) and five outcomes (exacerbation rate, lung function, asthma control, adherence, time to first exacerbation) were deemed feasible for inclusion in meta-analyses due to sufficient comparable reporting. Subgroups of clinical outcomes stratified by levels of patient traits were reported in 16 RCTs. A systematic review of studies of regular ICS dosing with SABA or ICS/formoterol-containing treatment strategies in asthma identified consistent reporting of five traits and outcomes, allowing exploration of associations with treatment response. Conversely, many other traits and outcomes, although being potentially relevant, were inconsistently reported and limited subgroup reporting meant analyses of treatment response for subgroups of traits was not possible. We recommend more consistent measurement and reporting of clinically relevant patient traits and outcomes in respiratory RCTs.

29 July 2023 in Respiratory Medicine
Verified
Journal Article
Open access
AYArzu Yorgancıoğlu
Arzu Yorgancıoğlu
ACAlvaro Augusto Cruz
Alvaro Augusto Cruz
GGGabriel Garcia
Gabriel Garcia
KLKim L. Lavoie
Kim L. Lavoie
NRNicolas Roche
Nicolas Roche
SCSwarnendu Chatterjee
Swarnendu Chatterjee
Current treatment for moderate-severe asthma with inhaled corticosteroid (ICS)-based therapy can follow two strategies: a single inhaler maintenance and reliever therapy (MART) regimen, or regular dosing with ICS/long-acting β2-agonist used as maintenance therapy plus a separate short acting β2-agonist reliever inhaler. It would be clinically useful to understand the potential of patient traits to influence regular dosing or MART treatment outcomes. A systematic literature review (SLR) and meta-analysis was conducted to identify specific patient traits that may predict improved clinical outcomes with regular dosing or MART. The SLR identified 28 studies in patients with moderate-severe asthma assessing regular dosing or MART treatments and reporting the traits and outcomes of interest. Network meta-regressions found no significant difference in the relative efficacy of regular dosing as compared with MART on any of the clinical outcomes (exacerbation rate, time to first exacerbation, FEV1, reliever use and adherence) for any of the patient traits (baseline lung function, baseline ACQ, age, BMI, and smoking history) evaluated. However, some trends towards traits influencing treatment efficacy were identified. Inconsistent reporting of traits and outcomes was observed between trials. The analysed patient traits evaluated in this study were associated with similar efficacy for the analysed outcomes to either regular dosing or MART; however, trends from the data observed encourage future analyses for possible identification of additional traits, or a combination of traits, that may be of interest. More comparable reporting of clinically important traits and outcomes would improve future analyses.

23 March 2025 in Respirar
Verified
Journal Article
Open access
PDF file
IZIgnacio Zabert
Ignacio Zabert
ASAna María Stok
Ana María Stok
CCCarmen Cano
Carmen Cano
PFPatricia Fernández
Patricia Fernández
MMMaria Felicia Montero-Arias
Maria Felicia Montero-Arias
GGGabriel García
Gabriel García
Asthma affects millions of people around the world, including Latin America. Severe asthma is often underdiagnosed, with difficulty in both access to appropriate treatment and access to quality health services and there is a low level of education on its management; this has a significant impact on morbidity and mortality and quality of life of patients. In the year 2020 we elaborated the ALAT Severe Asthma GUIDE, considering the need to update and develop new recommendations, we present this document based on the best available evidence to the year 2024. In this new Guideline 2024, the recommendations have been based on the best available evidence and have been agreed upon by a group of experts representing most of the Latin American medical societies that are members of ALAT. The modified Delphi panel was used to achieve an appropriate level of consensus for each of the recommendations included in this CPG. Six new topics were included, such as the role of inhaled triple therapy in the definition of severe asthma, the new concepts of asthma remission and treatment failure, the identification of risk factors for exacerbations, the efficacy and safety of biologics in the treatment of adults with severe corticosteroid-dependent asthma and, finally, the efficacy and safety of anti-TSLP antibodies (tezepelumab). A specific guideline for the management of severe asthma is essential to improve diagnosis, standardize treatments, reduce inequalities in care and strengthen health systems by making more efficient use of available resources.

1 December 2025 in Respirar
Verified
Journal Article
Open access
PDF file
ASAna Stok
Ana Stok
FAFrancisco Javier Alvarez-gutierrez
Francisco Javier Alvarez-gutierrez
MAMARINA BLANCO APARICIO
MARINA BLANCO APARICIO
FCFrancisco Casas-Maldonado
Francisco Casas-Maldonado
CCCarmen Cano
Carmen Cano
JCJosé Gregorio Soto Campos
José Gregorio Soto Campos
Asthma exacerbation is a significant clinical event that occurs with varying severity, yet a set of universally accepted standardized definitions is still needed. The aim of this consensus developed by ALAT and SEPAR was to fill this gap with a validated proposal for classifying asthma exacerbations into levels of severity: non-severe, severe, and very severe. The consensus was based on an in-depth review of the literature conducted by the scientific committee to identify key parameters for each level of severity, including worsening symptoms, respiratory function changes, and the need for specific medical interventions. A total of 67 publications were analyzed to generate a questionnaire on the defining elements of asthma exacerbations, and this was put to the vote. Twenty-eight international experts participated in the validation of characteristics and definitions of exacerbation severity following Delphi methodology. The resulting definitions clearly distinguish non-severe exacerbations (requiring minor adjustments in treatment) from severe exacerbations (requiring more intensive interventions, including longer systemic corticosteroid use or hospitalization) and very severe exacerbations (life-threatening events requiring intensive care). These definitions provide a standardized framework that facilitates comparison between clinical trials and optimizes patient care. This consensus lays the foundation for unifying management criteria in global clinical practice and fostering research on the efficacy of asthma treatments. It also underlines the importance of accurate classification in improving clinical outcomes and reducing the overall burden of disease.